New horizons in osteoarthritis
- PMID: 23568255
- DOI: 10.1093/ageing/aft043
New horizons in osteoarthritis
Abstract
Osteoarthritis (OA) is the most common type of arthritis worldwide and rapidly increasing with ageing populations. It is a major source of pain and disability for individuals and economic burden for health economies. Modern imaging, in particular magnetic resonance imaging (MRI), has helped us to understand that OA is a dynamic remodelling process involving all the structures within the joint. Inflammation is common in OA, with a high prevalence of synovitis seen on imaging, and this has been associated with joint pain. MRI detected changes within the subchondral bone are also common and associated with pain and structural progression. Targeting individual pathologies may offer potential new therapeutic options for OA; this is particularly important given the current treatments are often limited by side effects or lack of efficacy. New approaches to understanding the pathology and pain pathways in OA offer hope of novel analgesic options, for example, monoclonal antibodies against nerve growth factor and centrally acting drugs such as duloxetine, tapentadol and bradykinin receptor antagonists have all recently undergone trials in OA. While treatment for OA has until now relied on symptom management, for the first time, recent trials suggest that structure modification may be possible by treating the subchondral bone.
Similar articles
-
Structural associations of osteoarthritis pain: lessons from magnetic resonance imaging.Novartis Found Symp. 2004;260:191-201; discussion 201-5, 277-9. Novartis Found Symp. 2004. PMID: 15283451 Review.
-
Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial.Trials. 2013 Mar 2;14:64. doi: 10.1186/1745-6215-14-64. Trials. 2013. PMID: 23452375 Free PMC article. Clinical Trial.
-
Cannabis and joints: scientific evidence for the alleviation of osteoarthritis pain by cannabinoids.Curr Opin Pharmacol. 2018 Jun;40:104-109. doi: 10.1016/j.coph.2018.03.012. Epub 2018 Apr 7. Curr Opin Pharmacol. 2018. PMID: 29635215 Review.
-
Optimising pain control in osteoarthritis.Practitioner. 2010 Dec;254(1735):23-6, 2-3. Practitioner. 2010. PMID: 21306035
-
Predictors of functional impairment and pain in erosive osteoarthritis of the interphalangeal joints: comparison with controlled inflammatory arthritis.Arthritis Rheum. 2012 May;64(5):1430-6. doi: 10.1002/art.33502. Arthritis Rheum. 2012. PMID: 22139828
Cited by
-
Tapentadol in the treatment of osteoarthritis: pharmacological rationale and clinical evidence.J Pain Res. 2019 May 16;12:1529-1536. doi: 10.2147/JPR.S190161. eCollection 2019. J Pain Res. 2019. PMID: 31190964 Free PMC article. Review.
-
Delayed gadolinium-enhanced MRI of the meniscus (dGEMRIM) in patients with knee osteoarthritis: relation with meniscal degeneration on conventional MRI, reproducibility, and correlation with dGEMRIC.Eur Radiol. 2014 Sep;24(9):2261-70. doi: 10.1007/s00330-014-3204-z. Epub 2014 May 10. Eur Radiol. 2014. PMID: 24816941
-
The Use of Botulinum Toxin for the Treatment of Chronic Joint Pain: Clinical and Experimental Evidence.Toxins (Basel). 2020 May 10;12(5):314. doi: 10.3390/toxins12050314. Toxins (Basel). 2020. PMID: 32397671 Free PMC article. Review.
-
Temporomandibular joint diagnostics using CBCT.Dentomaxillofac Radiol. 2015;44(1):20140235. doi: 10.1259/dmfr.20140235. Dentomaxillofac Radiol. 2015. PMID: 25369205 Free PMC article. Review.
-
Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation.Pharmaceutics. 2023 Jun 20;15(6):1772. doi: 10.3390/pharmaceutics15061772. Pharmaceutics. 2023. PMID: 37376219 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical